Arrowhead Pharma
(ARWR)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 0 | 0 | 0 | 3,551 | 16,097 |
| Gross Profit | N/A | N/A | N/A | 3,551 | 16,097 |
| Operating Expenses | 162,203 | 176,141 | 126,191 | 140,096 | 124,427 |
| Operating Income | -162,203 | -176,141 | -126,191 | -136,545 | -108,330 |
| Interest Expense | 14,647 | 5,094 | 7,244 | 5,367 | 5,262 |
| Other Income | 4,052 | 7,258 | 6,439 | 3,223 | 4,602 |
| Pre-tax Income | -172,798 | -173,977 | -126,996 | -138,689 | -108,990 |
| Income Tax | 546 | N/A | N/A | -3,313 | 2,025 |
| Net Income Continuous | -173,344 | -173,977 | -126,996 | -135,376 | -111,015 |
| Minority Interests | -2,808 | -3,184 | -1,696 | -2,512 | -1,336 |
| Net Income | $-170,536 | $-170,793 | $-125,300 | $-132,864 | $-109,679 |
| EPS Basic Total Ops | -1.36 | -1.38 | -1.02 | -1.24 | -1.03 |
| EPS Basic Continuous Ops | -1.40 | -1.40 | -1.03 | -1.26 | -1.04 |
| EPS Diluted Total Ops | -1.36 | -1.38 | -1.02 | -1.24 | -1.02 |
| EPS Diluted Continuous Ops | -1.40 | -1.40 | -1.03 | -1.26 | -1.03 |
| EPS Diluted Before Non-Recurring Items | -1.38 | -1.38 | -1.02 | -1.24 | N/A |
| EBITDA(a) | $-168,308 | $-164,369 | $-119,935 | $-133,117 | $-105,458 |